The Latest Cardiac and Vascular News
ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces the appointment of François Guillet as Chief Financial Officer, replacing Éric Cohen who is leaving to pursue […]
July 26, 2024 02:00 AM Eastern Daylight Time PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces the conclusions of the futility analysis of […]
PARIS–(BUSINESS WIRE)–Regulatory News: “ACTISAVE Clinical Trial: Efficacy and Safety of Glenzocimab on Top of Thrombolysis with or without Mechanical Thrombectomy.” Post this ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for […]
PARIS–(BUSINESS WIRE)–Regulatory News: “ACTISAVE Clinical Trial: Efficacy and Safety of Glenzocimab on Top of Thrombolysis with or without Mechanical Thrombectomy” Post this ACTICOR BIOTECH (FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of glenzocimab, an innovative […]
PARIS–(BUSINESS WIRE)–Regulatory News: “ACTISAVE Clinical Trial: Efficacy and Satefy of Glenzocimab on Top of Thrombolysis with or without Mechanical Thrombectomy” Post this ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the […]
Capital increase consisting of an offer to qualified investors, categories of investors and individual investors via the PrimaryBid platform Subscription commitments from existing shareholders and new investors for a total of around 6.46 M€ Issue price of the new shares […]
ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of August 31, 2023 (pursuant […]
PARIS–(BUSINESS WIRE)–Acticor Biotech, (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today the results of its collaboration with Brainomix Limited, to further explore the imaging data using Artificial […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of […]
PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of May […]
